• Trial evidence suggests that the onset of Type 2 diabetes is greater in people taking a beta-blocker and thiazide combination compared with other drug combinations, and might lead to an increased incidence of diabetes of 0.4% per year of treatment (i.e. one additional case of diabetes for 250 people treated every year).
• A meta-analysis of seven trials (almost 77,000 people) found a higher incidence of diabetes in people taking beta-blockers and/or thiazide-type diuretics (about half received a beta-blocker and a thiazide) compared with people taking other antihypertensive drugs.
The increased risk was thought to be due to the combination of beta-blocker and thiazide-type diuretic rather than to the use of the drugs separately
The NICE guidelines on hypertension states:
Beta-blockers:
In head-to-head trials, beta-blockers were usually less effective than a comparator
drug at reducing major cardiovascular events, particularly stroke. Beta-blockers were also less
effective than an ACE inhibitor or a calcium channel blocker at reducing the risk of diabetes,
particularly in patients taking a beta-blocker and a thiazide-type diuretic.
If a beta-blocker is initiated in any of these circumstances, and a second drug is required, add a calcium-channel blocker rather than a thiazide-type diuretic, in order to reduce the person's risk of developing diabetes. There is evidence that the use of a beta-blocker and/or a thiazide-type diuretic may induce the onset of Type 2 diabetes in people at risk.”
Your GP would seem to have a few questions to answer about the prescribing........ :roll:
This again from the NICE guidelines might give a clue as to why .........
1.4.18
Prescribe non-proprietary drugs where these are appropriate and minimise cost.
• Drug treatment beginning with either a non-proprietary thiazide-type diuretic or beta-blocker minimises cost.
• From a model of lifetime costs and effects, based on the findings of trials, treatment using stepped care including thiazide-type diuretics, beta-blockers, ACE-inhibitors/angiotensin receptor blockers and calcium-channel blockers is estimated to be cost effective.